Search

Author/Creator Winner, Paul

1. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. (January 2020)

Authors:
Brandes, Jan Lewis; Diener, Hans-Christoph; Dolezil, David; Freeman, Marshall C; McAllister, Peter J; Winner, Paul; Klatt, Jan; Cheng, Sunfa; Zhang, Feng; Wen, Shihua; Ritter, Shannon; Lenz, Robert A; Mikol, Daniel D
Journal:
Cephalalgia
Issue:
Volume 40:Number 1(2020)
Page Start:
28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. (May 2020)

Authors:
Tepper, Stewart J; Ashina, Messoud; Reuter, Uwe; Brandes, Jan Lewis; Doležil, David; Silberstein, Stephen D; Winner, Paul; Zhang, Feng; Cheng, Sunfa; Mikol, Daniel D
Journal:
Cephalalgia
Issue:
Volume 40:Number 6(2020)
Page Start:
543
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer's disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial. (20th December 2022)

Authors:
Moebius, Hans J.; Bernick, Charles B.; Winner, Paul; Maalouf, Joyce; Ooi, Kai‐Bin; Dickson, Samuel P.; Hendrix, Suzanne B.; Church, Kevin; Olichney, John M.
Journal:
Alzheimer's & dementia
Issue:
Volume 18(2022)Supplement 10
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Issue 6 (June 2017)

Authors:
Tepper, Stewart; Ashina, Messoud; Reuter, Uwe; Brandes, Jan L; Doležil, David; Silberstein, Stephen; Winner, Paul; Leonardi, Dean; Mikol, Daniel; Lenz, Robert
Journal:
Lancet neurology
Issue:
Volume 16:Issue 6(2017:Jun.)
Page Start:
425
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double‐blind, multi‐center, parallel‐group study (TEENZ). Issue 7 (22nd June 2016)

Authors:
Winner, Paul; Farkas, Viktor; Štillová, Helena; Woodruff, Brian; Liss, Charlie; Lillieborg, Stefan; Raines, Shane
Journal:
Headache
Issue:
Volume 56:Issue 7(2016)
Page Start:
1107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Issue 8 (7th August 2021)

Authors:
Smith, Timothy R.; Winner, Paul; Aurora, Sheena K.; Jeleva, Maria; Hocevar‐Trnka, Jasna; Shrewsbury, Stephen B.
Journal:
Headache
Issue:
Volume 61:Issue 8(2021)
Page Start:
1214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗